Bamboo polypeptide with antihypertensive activity and preparation method and application thereof

The bamboo polypeptide prepared by fermentation of bamboo shoots, bamboo shoots and tender bamboos solves the problem of poor antihypertensive effect of polypeptide substances in the prior art, achieves significant ACE inhibition, is suitable for health care products and functional foods, and provides safety Efficient bucking solution.

CN118894907APending Publication Date: 2024-11-05INT CENT FOR BAMBOO & RATTAN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411030419.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The polypeptide substances reported in the prior art have poor antihypertensive effects, and naturally-derived ACE inhibitor drugs often cause side effects when taken, so we seek a natural antihypertensive drug with obvious ACE inhibitory effect.

Method used

By using bamboo shoots, bamboo shoots, and tender bamboo as raw materials, using Bacillus upland ICBR-C01 fermentation, bamboo polypeptides with molecular weight less than 3kDa were prepared, with significant ACE inhibitory activity, and amino acid sequences such as SEQ ID NO.1 and SEQ ID NO. The IC50 of the bamboo polypeptide of 2 to ACE was 11.4783μM and 11.7883μM, respectively.

Benefits of technology

Bamboo polypeptide has obvious ACE inhibitory effect, and has advantages over the reported ACE inhibitory peptides. It is suitable for the preparation of health products and functional foods with auxiliary antihypertensive function, and has broad market application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894907A_ABST
    Figure CN118894907A_ABST
Patent Text Reader

Abstract

The invention provides bamboo polypeptide with antihypertensive activity and a preparation method and application thereof, and belongs to the technical field of food biology. The invention provides bamboo polypeptide with antihypertensive activity. The bamboo polypeptide comprises bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.1 and / or bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.2. The bamboo polypeptide is prepared by taking bamboo shoots, retreated bamboo shoots and tender bamboos as raw materials and fermenting the bamboo shoots, the retreated bamboo shoots and the tender bamboos through bacillus altitudinis ICBR-C01, the polypeptide has an obvious ACE (Angiotensin Converting Enzyme) inhibition effect, a molecular docking result of the polypeptide and ACE is relatively good, and IC50 of the polypeptide to the ACE is 11.4783 mu M and 11.7883 mu M respectively. Compared with reported ACE inhibitory peptide, the bamboo polypeptide has obvious advantages and can be applied to preparation of health care products and functional food with an auxiliary blood pressure lowering function.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of food biotechnology, and specifically relates to a bamboo polypeptide with blood pressure lowering activity and a preparation method and application thereof. Background Art

[0002] Hypertension is a clinical syndrome characterized by increased systemic arterial blood pressure (systolic and / or diastolic blood pressure) (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg), which may be accompanied by functional or organic damage to organs such as the heart, brain and kidneys. It is the most common chronic non-communicable disease. Increased blood pressure is the trigger for many diseases, increasing the risk of coronary heart disease, heart failure, kidney disease and other diseases, and is also a major risk factor for stroke. Because some hypertensive patients have no obvious clinical symptoms, hypertension is also called the "invisible killer" of human health. Therefore, the prevention and treatment of hypertension has become the focus of today's society.

[0003] The blood pressure regulation mechanism of the human body is very complex, but it mainly relies on the coordination of the renin-angiotensin system (RAS) and the kininase-kinin releasing system (KKS) to maintain stability. Among them, based on the understanding of the renin-angiotensin-aldosterone (RAAS) system in the human kidney, the analysis of the action mechanism of angiotensin converting enzyme (ACE) is considered an important breakthrough in the treatment of hypertension. The RAAS system is a pressure regulation system produced by the kidneys. ACE is a key enzyme in the RAAS system. It catalyzes the production of vasoconstrictive Ang II, leading to vascular wall contraction and increased blood pressure; at the same time, ACE acts on bradykinin with vasodilatory activity, promotes its degradation and inactivation, and indirectly causes an increase in blood pressure. Inhibiting the activity of ACE is considered to be a key step in achieving a hypotensive effect. Its hypotensive principle is mainly to block the RAAS system and inhibit the activity of ACE, thereby inhibiting the conversion of circulating and local tissue angiotensin I into angiotensin II, reducing the production of angiotensin II and inhibiting the degradation of bradykinin, thereby playing a role in vasodilation and lowering blood pressure.

[0004] At present, the drugs widely used to treat hypertension are mainly ACE inhibitors such as captopril, lisinopril, enalapril and perindopril. However, taking drugs to treat hypertension usually causes side effects. Natural ACE inhibitory peptides have attracted much attention from researchers because of their high safety. Since the first ACE inhibitory peptide was discovered in 1965, researchers have obtained more than 6,000 ACE inhibitory peptides from natural proteins from various sources, most of which are derived from food. At present, the antihypertensive activity of the tripeptides VPP and IPP extracted from milk β-casein and κ-casein, respectively, has been further confirmed in animal experiments and clinical trials. However, the peptide substances reported so far generally have the problem of poor antihypertensive effect. Summary of the invention

[0005] In view of the defects in the prior art, the purpose of the present invention is to provide a bamboo polypeptide with antihypertensive activity, which has a significant ACE inhibitory effect and has obvious advantages in lowering blood pressure.

[0006] The objective of the present invention is achieved through the following technical solutions:

[0007] The present invention provides a bamboo polypeptide with antihypertensive activity, wherein the bamboo polypeptide comprises: a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.1 and / or a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.2.

[0008] The present invention provides a method for preparing the bamboo polypeptide described in the above technical solution, comprising the following steps:

[0009] fermenting the bamboo homogenate to obtain a fermentation liquid;

[0010] The polypeptides with molecular weight less than 3 kDa in the fermentation broth are collected to obtain bamboo polypeptides.

[0011] Preferably, the fermentation bacterial agent includes Bacillus altitudinis ICBR-C01; the deposit number of the Bacillus altitudinis ICBR-C01 is CGMCC No.29900.

[0012] Preferably, during fermentation, the inoculation amount of the bacterial agent used is 6% to 10% of the volume of the bamboo homogenate; the bacterial activity of the bacterial agent used is 1×10 6 ~1×10 8 CFU / mL.

[0013] Preferably, the fermentation includes aerobic fermentation; the fermentation time is 8 to 15 hours; the fermentation temperature is 20° C. to 37° C., and the fermentation is accompanied by stirring; the stirring speed is 150 to 200 rpm.

[0014] Preferably, the method for preparing the bamboo homogenate comprises the following steps:

[0015] The bamboo raw material is crushed and mixed with water, and then homogenized to obtain a bamboo homogenate;

[0016] The material-liquid ratio of the bamboo raw material and water is 1kg:(5-15)L.

[0017] Preferably, the bamboo raw material includes any one or more of bamboo shoots, old bamboo shoots and young bamboo.

[0018] The present invention provides the use of the bamboo polypeptide described in the above technical solution or the bamboo polypeptide prepared by the preparation method described in the above technical solution in the preparation of a blood pressure reducing product.

[0019] Preferably, the product comprises a health product and / or a functional food.

[0020] Beneficial effects of the present invention:

[0021] The present invention provides a bamboo polypeptide with antihypertensive activity, and the bamboo polypeptide comprises: a bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.1 and / or a bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.2. The bamboo polypeptide provided by the present invention is obtained by using bamboo shoots, bamboo shoots and tender bamboo (bamboo within one year) as raw materials to obtain a polypeptide with antihypertensive activity, and the molecular docking result of the polypeptide with ACE is good, and it has good binding ability with the corresponding target. The IC of the bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.1 and the bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.2 on ACE is verified by ACE inhibitory activity assay. 50 The bamboo polypeptide has obvious ACE inhibitory effect. Compared with the reported ACE inhibitory peptides, the bamboo polypeptide of the present invention has obvious advantages, can be used to prepare health products and functional foods with auxiliary blood pressure lowering function, and has broad market application prospects.

[0022] Biological Deposit Description

[0023] Bacillus altitudinis ICBR-C01 was deposited in the General Microbiology Center (CGMCC) of the China Microorganism Culture Collection Administration on February 27, 2024, with the deposit number CGMCC No.29900. The address of the deposit unit is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0025] Figure 1 Total ion chromatogram before fermentation was detected by LC-MS / MS;

[0026] Figure 2 Total ion chromatogram after fermentation was detected by LC-MS / MS;

[0027] Figure 3 The mass spectrum diagram of the structure identification of the bamboo polypeptide whose amino acid sequence is shown in SEQ ID NO.1;

[0028] Figure 4 The mass spectrum diagram of the structure identification of the bamboo polypeptide whose amino acid sequence is shown in SEQ ID NO.2;

[0029] Figure 5 The 3D view of the optimal conformation of the molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE;

[0030] Figure 6 It is a partial diagram of molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE;

[0031] Figure 7 The 2D diagram of the molecular docking interaction between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE;

[0032] Figure 8 The 3D view of the optimal conformation of the molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 and ACE;

[0033] Fig. 9 It is a partial diagram of molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 and ACE;

[0034] Fig.10 The 2D diagram of the molecular docking interaction between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 and ACE;

[0035] Fig.11 The mass spectrum diagram of the structure identification of the bamboo polypeptide whose amino acid sequence is shown in SEQ ID NO.1;

[0036] Fig.12 This is a mass spectrum diagram for structural identification of a bamboo polypeptide whose amino acid sequence is shown in SEQ ID NO.2. DETAILED DESCRIPTION

[0037] The present invention provides a bamboo polypeptide with antihypertensive activity, wherein the bamboo polypeptide comprises: a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.1 and / or a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.2.

[0038] In the present invention, the bamboo polypeptide can be respectively referred to as bamboo shoot polypeptide, bamboo shoot polypeptide and tender bamboo polypeptide according to different raw materials.

[0039] In the present invention, the bamboo polypeptide can be directly prepared by a conventional polypeptide synthesis method, or can be prepared by the preparation method provided by the present invention.

[0040] The present invention provides a method for preparing the bamboo polypeptide described in the above technical solution, comprising the following steps:

[0041] fermenting the bamboo homogenate to obtain a fermentation liquid;

[0042] The polypeptides with molecular weight less than 3 kDa in the fermentation broth are collected to obtain bamboo polypeptides.

[0043] The present invention ferments bamboo homogenate to obtain fermentation liquid. In the present invention, the preparation method of the bamboo homogenate preferably includes the following steps: crushing the bamboo raw material and mixing it with water, and then homogenizing to obtain bamboo homogenate; the material-liquid ratio of the bamboo raw material and water is preferably 1kg: (5-15)L. In the present invention, the bamboo raw material preferably includes any one or more of bamboo shoots, old bamboo shoots and young bamboo; the young bamboo preferably includes bamboo within one year; the bamboo shoots preferably include bamboo shoot processing residues. The present invention has no special limitation on the source of the bamboo raw material, and any conventional bamboo raw material in the field can be used. After obtaining the bamboo raw material, the present invention preferably shells, washes and cuts the bamboo raw material in sequence before crushing it. The present invention has no special limitation on the shelling, washing, cutting and crushing methods, and any conventional method can be used. The crushed volume of the present invention is preferably 2mm 3 . After crushing, the present invention preferably obtains a crushed material. After obtaining the crushed material, the present invention preferably mixes the crushed material with water to obtain a mixed material; the material-liquid ratio of the crushed material and water is preferably 1kg:(5-15)L, more preferably 1kg:10L. In the present invention, the water preferably includes distilled water. After obtaining the mixed material, the present invention preferably homogenizes the mixed material; the present invention has no special limitation on the method of homogenization, and any conventional homogenization method in the field can be used; the homogenization of the present invention is preferably carried out at room temperature. After the homogenization is completed, the present invention obtains a bamboo homogenate.

[0044] After obtaining the bamboo homogenate, the present invention preferably ferments the bamboo homogenate. After obtaining the bamboo homogenate, the present invention preferably sterilizes the bamboo homogenate before fermenting; the present invention has no special restrictions on the sterilization conditions, and any conventional sterilization method can be used. In the present invention, the sterilization temperature is preferably 121°C; the sterilization time is preferably 20 minutes. In the present invention, the fermentation bacterial agent preferably includes Bacillus subtilis ICBR-C01; the preservation number of Bacillus subtilis ICBR-C01 is CGMCC No. 29900. When the present invention is fermented, the inoculation amount of the bacterial agent used is 6% to 10% of the volume of the bamboo homogenate, more preferably 8%; the bacterial activity of the bacterial agent used is preferably 1×10 6 ~1×10 8 CFU / mL, more preferably 1×10 7 CFU / mL. Furthermore, when the present invention is fermented, it is preferred that the bacterial activity is 1×10 7The bacterial liquid with CFU / mL is inoculated at 6% to 10% of the volume of the bamboo homogenate. The fermentation of the present invention preferably includes aerobic fermentation; the temperature of the fermentation is preferably 20°C to 37°C, more preferably 37°C; the fermentation time is preferably 8 to 15h, more preferably 12h; the fermentation is preferably accompanied by stirring; the stirring speed is preferably 150 to 200rpm, more preferably 200rpm. In the present invention, the fermentation is preferably carried out in a temperature-controlled shaker. After the fermentation is completed, the present invention preferably centrifuges the fermentation product and filters it to obtain a fermentation liquid; the centrifugal speed is preferably 6000rpm; the centrifugal time is preferably 10min; after the centrifugation is completed, the present invention preferably performs filtration; the filtration is preferably performed using a 0.22μm filter membrane. The present invention uses a 0.22μm filter membrane for filtration mainly to filter out the fermentation bacteria to terminate the fermentation. After the filtration is completed, the present invention takes the filtrate to obtain the fermentation liquid.

[0045] After obtaining the fermentation liquid, the present invention collects polypeptides with a molecular weight less than 3 kDa in the fermentation liquid to obtain bamboo polypeptides. In the present invention, the collection method preferably includes centrifugal ultrafiltration. The centrifugal ultrafiltration is preferably performed using an ultrafiltration centrifuge tube; the molecular weight cutoff of the ultrafiltration centrifuge tube is preferably 3 kDa; the speed of the centrifugation is preferably 10000 rpm; and the time of the centrifugation is preferably 20 min. After the centrifugation is completed, the present invention collects the filtrate, and the bamboo polypeptide is present in the filtrate.

[0046] After obtaining the bamboo polypeptide, the present invention preferably identifies the bamboo polypeptide and then screens for ACE inhibitory peptides to obtain bamboo polypeptides with antihypertensive activity. In the present invention, the identification method preferably includes LC-MS / MS detection, database retrieval and peptide group analysis. The present invention does not specifically limit the specific method of the identification, and conventional methods in the art can be used. The present invention preferably obtains the newly generated polypeptide sequence in the fermentation broth by peptide group analysis. After obtaining the polypeptide sequence, the present invention preferably analyzes the amino acid structure by polypeptide sequence, and uses a polypeptide activity prediction tool to screen ACE inhibitory peptides.

[0047] The bamboo polypeptide prepared by the preparation method of the technical solution of the present invention has a good molecular docking result with ACE and has a good binding ability with the corresponding target. The IC of the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 to ACE is verified by the ACE inhibitory activity assay. 50 The bamboo polypeptide has obvious ACE inhibitory effect.

[0048] The present invention provides the use of the bamboo polypeptide described in the above technical solution or the bamboo polypeptide prepared by the preparation method described in the above technical solution in the preparation of a blood pressure-lowering product. In the present invention, the product includes a health product and / or a functional food. Compared with the reported ACE inhibitory peptide, the bamboo polypeptide of the present invention has obvious advantages, can be used to prepare health products and functional foods with auxiliary blood pressure-lowering function, and has broad market application prospects.

[0049] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0050] Example 1

[0051] Bamboo shoot polypeptide, the preparation method thereof is specifically as follows:

[0052] 1. Preparation of Fermentation Broth

[0053] Shell the bamboo shoots, clean them, cut them into pieces and crush them into 2mm pieces 3 The bamboo shoots were homogenized at a ratio of 1 kg to 10 L of distilled water at room temperature. After obtaining the homogenate, the homogenate was sterilized at 121°C for 20 min to prepare the bamboo shoot homogenate. Bacillus altitudinis ICBR-C01 bacterial solution was inoculated into the bamboo shoot homogenate at an inoculation rate of 8% (v:v). The bacterial activity of the bacterial solution was 1×10 7 CFU / mL. Ferment aerobically at 37°C for 12 hours, place in a temperature-controlled shaker at 200 rpm, transfer the fermentation liquid into a centrifuge tube and centrifuge at 6000 rpm for 10 minutes, and filter the supernatant through a 0.22 μm filter to terminate the reaction.

[0054] 2. Recovery of Low Molecular Weight Peptides

[0055] The polypeptides with molecular weight less than 3 kDa were recovered by centrifugal ultrafiltration. 0.5 mL of the supernatant after centrifugation was placed in a 2 mL ultrafiltration centrifuge tube with a molecular weight cutoff of 3 kDa, centrifuged at 10,000 rpm for 20 min, and the filtrate was collected. The filtrate contained the bamboo shoot polypeptides.

[0056] 3. Sample reductive alkylation pretreatment

[0057] (1) Take the bamboo shoot polypeptide filtrate sample in step 2, add a 1 M dithiothreitol solution to make the final dithiothreitol concentration in the bamboo shoot polypeptide filtrate sample 10 mmol / L, and reduce it in a 56° C. water bath for 1 h;

[0058] (2) Add 10 mM iodoacetamide solution to a final concentration of 50 mmol / L and react for 40 min in the dark;

[0059] (3) Desalt the solution using a self-packed desalting column and evaporate the solvent in a vacuum centrifugal concentrator at 45°C.

[0060] 4. Identification of bamboo shoot peptides

[0061] LC-MS / MS detection was used, and the specific conditions and steps were as follows:

[0062] (1) Liquid chromatography conditions

[0063] ①Analytical column: AcclaimTM PepMapTM RPLC C18 (150μm ID×150mm, 3μm, );

[0064] ②Mobile phase A: 0.1% formic acid aqueous solution;

[0065] ③ Mobile phase B: 80% acetonitrile (containing 0.1% formic acid) aqueous solution;

[0066] ④Flow rate: 600nL / min;

[0067] ⑤Analysis time: 66min;

[0068] (2) Mass spectrometry conditions

[0069] ① Primary mass spectrometry parameters: Resolution: 120,000; AGCtarget: Standard; MaximumIT: 20ms; Scanrange: 300 to 1800 m / z.

[0070] ② Secondary mass spectrometry parameters: Resolution: 50,000; AGCtarget: Standard; MaximumIT: 22ms; TopN: 20; NCE / steppedNCE: 30.

[0071] (3) LC-MS / MS detection

[0072] When detecting bamboo shoot peptides before fermentation, 100 μL of the filtrate after the bamboo shoot homogenate was filtered through a 0.22 μm filter membrane was taken, and the sample was pre-treated by reduction alkylation before LC-MS / MS detection. The LC-MS / MS detection results are as follows: Figure 1 shown.

[0073] When detecting bamboo shoot polypeptides in the fermented filtrate, the sample after reduction alkylation treatment in step 3 was taken for LC-MS / MS detection. The LC-MS / MS detection results are as follows: Figure 2 shown.

[0074] in Figure 1 Total ion chromatogram before fermentation was detected by LC-MS / MS; Figure 2 The total ion current after fermentation was detected by LC-MS / MS. Figure 1 and Figure 2 The horizontal axis represents time (min); the vertical axis represents relative abundance.

[0075] Figure 1 41.17,43.43,43.97,44.77,45.10,46.04,46.96,49.70,52.09,53.02,55.47,61.70,62.18,64.77,65.81,66.70,70.71,71.91,72.13,73.70,73.71,74.77,75.91,76.81,77.91,78.61,79.80,81.16,83.70,84.70,85.91,86.81,87.91,88.61,89.80,90.10

[0076] Figure 2 The numbers from left to right are 1.86, 4.07, 5.63, 5.90, 6.79, 6.95, 8.69, 9.39, 9.45, 9.78, 10.01, 10.11, 11.29, 14.23, 15.29, 17.69, 18.11, 19.23, 20.67, 23.04, 24.64, 27.14, 28.90, 30.52, 30.97, 32.93, 33.61, 34.65, 36.43, 36.68, 39.04, 40.49, 42.27, 42.77, 43.56, 45.01, 46.31, 47.24, 50.08, 50.17, 51.26, 54.35, 54.41, 54.78, 54.89, 55.24.

[0077] 3) Database search

[0078] The mass spectrometry raw files were searched against the target protein database using Peaks Studio 10.6, and the search parameters were as follows: fixed modifications: Carbamidomethyl (C); variable modifications: Oxidation (M), Acetyl (Peptide N-term); Enzyme: None; Database: Phyllostachys edulis; Maximum Missed Cleavages: 2; Primary mass spectrometry error (Peptide Mass Tolerance): 20 ppm; Secondary mass spectrometry error (Fragment Mass Tolerance): 0.02 Da.

[0079] 4. Screening of ACE inhibitory peptides

[0080] (1) After LC-MS / MS detection, the original downloaded data was directly submitted to Peaks Studio 10.6 for target protein database retrieval, and common contaminating proteins and their matching peptides were filtered out to obtain the peptide sequence results identified for each sample. Peaks Studio 10.6 was used to perform target protein database retrieval and peptidomics analysis to obtain the peptide sequences newly produced after fermentation.

[0081] Peptidomics identified a total of 65 peptides before and after fermentation of the bamboo shoots, including 35 peptides before fermentation and 53 peptides after fermentation. Among them, there were 23 peptides shared by both before and after fermentation.

[0082] Among them, the amino acid sequence of the bamboo polypeptide shown in SEQ ID NO.1 (SIHKVPL) is shown in the structural identification diagram Figure 3 The amino acid sequence of the bamboo polypeptide shown in SEQ ID NO.2 (EEHPVLL) is shown in the structural identification diagram Figure 4 As shown. Among them, Figure 3 The horizontal axis represents m / z, the vertical axis represents %intensity, and the number on the peak graph is 792.948; Figure 4 The horizontal axis in the figure represents m / z, the vertical axis represents %intensity, and the numbers on the peak graph from left to right are 835.970 and 857.976. Figure 3 and Figure 4 For clear viewing, it provides Fig.11 and Fig.12 ,in Fig.11 for Figure 3 A magnified image of Fig.12 for Figure 4Magnified image of .

[0083] The amino acid structure was analyzed and ACE inhibitory peptides were preliminarily screened using peptide activity prediction tools.

[0084] (2) The crystal structure of ACE was obtained from the RCSB PDB database (PDB ID: 1O8A). The protein crystals were processed by the Protein Preparation Wizard module of Schrödinger software, including protein preprocessing, regenerate states of native ligand, H-bond assignment optimization, protein energy minimization, and water removal.

[0085] (3) The Peptide option in the Build Biopolymer from Sequence module was used to model the ACE inhibitory peptides that were initially screened, and the Protein Preparation Wizard module was used to pretreat the peptides.

[0086] (4) First, use the SiteMap module in Schrödinger to predict the best binding site, and then use the Receptor Grid Generation module in Schrödinger to set the most appropriate Enclosing box to perfectly enclose the predicted binding site, and on this basis, obtain the protein active site that is only suitable for peptide docking.

[0087] (5) The Peptide Docking module was used to perform peptide-protein docking on the processed peptides and the corresponding proteins, and the number of peptide docking poses was set to 10. The lower the docking score, the higher the possibility of binding between the peptide and the protein.

[0088] (6) The active sites of the peptide and the corresponding protein were subjected to MM-GBSA calculation analysis. MM-GBSA dG Bind can approximately represent the binding free energy of the ligand and the protein. The lower the binding free energy, the higher the binding stability of the ligand and the protein.

[0089] (7) The different chains of the peptide-protein interaction complex with the lowest docking score and binding free energy are marked with different colors, and the Surface is added to display a 3D stereoscopic view. In addition, the Protein Interaction Analysis module is used to determine the specific segment of peptide-protein binding.

[0090] Comprehensive analysis of docking and MM-GBSA results Figures 5 to 10 shown. Figure 5 The 3D view of the optimal conformation of the molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE; Figure 6 It is a partial diagram of molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE; Figure 7 The 2D diagram of the molecular docking interaction between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and ACE; Figure 8 The 3D view of the optimal conformation of the molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 and ACE; Fig. 9 It is a partial diagram of molecular docking between the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 and ACE; Fig.10 It is a 2D diagram of the molecular docking interaction between the bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.2 and ACE.

[0091] The docking score of bamboo polypeptide with amino acid sequence as shown in SIHKVPL (SEQ ID NO. 1) and ACE is -9.619, and the MM-GBSA result is -26.96 kcal / mol. The docking score is very low and the binding free energy is low, indicating that SIHKVPL binds ACE stably.

[0092] The docking score of the bamboo polypeptide with the amino acid sequence shown as EEHPVLL (SEQ ID NO. 2) and ACE was -5.115, and the MM-GBSA result was -21.77 kcal / mol. Both the binding free energy and the docking score were low, indicating that the binding of EEHPVLL to ACE was relatively stable.

[0093] Depend on Figures 5 to 10 It can be seen that the bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.1 (SIHKVPL) penetrates deep into the active pocket of ACE, forms one hydrogen bond with each of the residues ASP358, TYR523, ALA354, GLU384, HIE513, and GLN281 of ACE, and forms two hydrogen bonds with the residue ALA356.

[0094] The bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.2 (EEHPVLL) penetrates deep into the active pocket of ACE, forms one hydrogen bond with each of the residues ALA354, TYR523, HIP383, SER516, ARG124, and TYR62 of ACE, forms two hydrogen bonds with the residue ALA356, forms a π-π bond with the residue TRP357, forms a hydrogen bond and a salt bridge with the residue ARG522, and forms a van der Waals force with the residue VAL518.

[0095] Example 2

[0096] ACE inhibition rate of antihypertensive peptides from bamboo shoots

[0097] The bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.1 and the bamboo polypeptide with the amino acid sequence shown in SEQ ID NO.2 are respectively solid-phase synthesized according to conventional methods.

[0098] Solid phase synthesis is a conventional method. The specific synthesis sequence is as follows: from the C-terminus to the N-terminus of the sequence: a. Weigh n equivalents of resin and put them into a reactor. Add DCM (dichloromethane) to swell for half an hour, then remove the DCM, add 2n equivalents of the first amino acid in the sequence, add 2n equivalents of DIEA, appropriate amounts of DMF and DCM (appropriate amounts refer to the amount that can fully agitate the resin), DIEA (diisopropylethylamine), DMF (dimethylformamide), DCM, and react with nitrogen bubbling for 60 minutes. Then add about 5n equivalents of methanol, react for half an hour, remove the reaction liquid, and wash with DMF and MeOH; b. Add the second amino acid in the sequence (also 2n equivalents), 2n equivalents of HBTU (benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) and DIEA to the reactor, react with N2 bubbling for half an hour, wash off the liquid, detect with ninhydrin, and then cap with pyridine and acetic anhydride. Finally, wash, add an appropriate amount of decapping liquid to remove the Fmoc (9-fluorenylmethoxycarbonyl) protecting group, wash, and detect with ninhydrin; c. Add different amino acids in the sequence in sequence and perform various modifications in the same manner as in step b; d. After the resin is dried with nitrogen, remove it from the reaction column and pour it into a flask, and then add a certain amount (the ratio of cutting liquid to resin is about 10mL / g) of cutting liquid (composed of 95% TFA, 2% ethanedithiol, 2% triisopropylsilane, 1% water) to the flask, shake, and filter out the resin; e. Obtain the filtrate, then add a large amount of ether to the filtrate to precipitate the crude product, and then centrifuge and wash to obtain the crude product of the sequence;

[0099] Polypeptide purification: The crude product obtained above is purified to the required purity by high performance liquid chromatography.

[0100] Peptide freeze-drying: The purified liquid is placed in a freeze dryer for concentration and freeze-dried into white powder.

[0101] Peptide detection: The purity and molecular weight of the synthesized peptide were identified by RP-HPLC and LC / MS, and it was determined that the purity of the obtained peptide was >95%.

[0102] N-(3-(2-furanoyl)acryloyl-phenylamino-glutamyl-glutamic acid (FAPGG, λmax=340nm, ε=2270M -1 cm -1, molecular weight 399.40) can be hydrolyzed by ACE into N-[3-(furano)acryloyl]-2-phenylalanine (FAP, λmax=340nm, ε=1512M -1 cm -1 ) and glycine (GG, no absorption at 340nm), so it can be used as a simulated substrate of ACE. The absorbance value of 1mM FAPGG completely converted into FAP and GG is 0.758, so the inhibition rate can be calculated based on the change in absorbance at 340nm.

[0103] The angiotensin converting enzyme (ACE) inhibitor activity assay kit (Solarbio BC5575) was used to detect the inhibitory activity of the samples on angiotensin converting enzyme (ACE) according to the instructions. Captopril was used as a positive control.

[0104] The inhibitory activities of the bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.1, the bamboo polypeptide with an amino acid sequence as shown in SEQ ID NO.2 and the positive control group on ACE are shown in Table 1.

[0105] Table 1 Inhibitory activity of two peptides on ACE

[0106]

[0107] As shown in Table 1, the IC values ​​of the bamboo polypeptide with amino acid sequence as shown in SEQ ID NO.1 and the bamboo polypeptide with amino acid sequence as shown in SEQ ID NO.2 for ACE are 50 They are 11.4783μM and 11.7883μM respectively, indicating that it has good ACE inhibitory activity.

[0108] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A bamboo polypeptide with antihypertensive activity, It is characterized in that The bamboo polypeptide comprises: a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.1 and / or a bamboo polypeptide having an amino acid sequence as shown in SEQ ID NO.

2.

2. A method for preparing the bamboo polypeptide according to claim 1, It is characterized in that The following steps are involved: fermenting the bamboo homogenate to obtain a fermentation liquid; The polypeptides with molecular weight less than 3 kDa in the fermentation broth are collected to obtain bamboo polypeptides.

3. The preparation method according to claim 2, It is characterized in that The fermentation bacterial agent includes Bacillus altitudinis ICBR-C01; the deposit number of the Bacillus altitudinis ICBR-C01 is CGMCC No.29900.

4. The preparation method according to claim 2 or 3, It is characterized in that During fermentation, the inoculation amount of the bacterial agent used is 6% to 10% of the volume of the bamboo homogenate, and the bacterial activity of the bacterial agent used is 1×10 6 ~1×10 8 CFU / mL.

5. The preparation method according to claim 2, It is characterized in that The fermentation includes aerobic fermentation; the fermentation time is 8 to 15 hours; the fermentation temperature is 20° C. to 37° C.; the fermentation is accompanied by stirring; the stirring speed is 150 to 200 rpm.

6. The preparation method according to claim 2, It is characterized in that The preparation method of the bamboo homogenate comprises the following steps: The bamboo raw material is crushed and mixed with water, and then homogenized to obtain a bamboo homogenate; The material-liquid ratio of the bamboo raw material and water is 1kg:(5-15)L.

7. The preparation method according to claim 6, It is characterized in that The bamboo raw materials include any one or two or more of bamboo shoots, old bamboo shoots and young bamboo.

8. Use of the bamboo polypeptide according to claim 1 or the bamboo polypeptide prepared by the preparation method according to any one of claims 2 to 7 in the preparation of blood pressure reducing products.

9. The use according to claim 8, It is characterized in that The products include health products and / or functional foods.